Pricing Log in Create free account
Friday 6 November 2026 Export CGON’s income statement to Excel — free account

CG Oncology, Inc.

CGON Healthcare Biotechnology

CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.

Revenue
−3.72%
EPS
−12.3%
Free cash flow
−25.2%
Total debt
0.00%

Quarter to September 2026, against a year earlier

76.08 11.28 +17.41%
Market cap
$5.7B
P/E
0.0×
Fwd P/E
−19.5×
Dividend yield
—
F-score
2/9
Altman Z
49.04
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

CG Oncology, Inc. (CGON) EPS (diluted)

Alert me on EPS (diluted)

CG Oncology, Inc.'s EPS (diluted) for fiscal 2025 was −$2.08, compared with −$1.41 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$2.76. CG Oncology, Inc. ranks 357th of 580 Biotechnology companies by EPS (diluted).

EPS (diluted), annual

Embed this chart

Annual newest first

Period EPS (diluted) Change
FY2025 −$2.08 —
FY2024 −$1.41 —
FY2023 −$15.65 —
FY2022 −$11.71 —

Quarterly newest first

Period EPS (diluted) Change
Sep 2026 −$0.64 —
Jun 2026 −$0.90 —
Mar 2026 −$0.71 —
Dec 2025 −$0.51 —
11 more quarters

EPS (diluted) against peers

Company EPS (diluted)
LGND Ligand Pharmaceuticals Incorporated compare $2.24
PTCT PTC Therapeutics, Inc. compare −$1.40
CGON CG Oncology, Inc. −$2.69
BLTE Belite Bio, Inc. Sponsored ADR compare −$2.73
IMVT Immunovant, Inc. compare −$2.82
SRRK Scholar Rock Holding Corporation compare −$3.32
KOD Kodiak Sciences Inc. compare −$4.19
MIRM Mirum Pharmaceuticals, Inc. compare −$15.22
MANE Veradermics Incorporated compare −$45.88

What EPS (diluted) is

Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.

Reported line item

The full definition of EPS (diluted) →

More on CGON